People who had earlier Covid-19 less likely to get Delta than those vaccinated with Pfizer
But giving even a single shot of the vaccine to those who were previously infected also seems to boost their protection
People who recovered from a bout of Covid-19 during one of the earlier waves of the pandemic appear to have a lower risk of contracting the Delta variant than those who got two doses of the vaccine from Pfizer and BioNTech.
The largest real-world analysis comparing natural immunity — gained from an earlier infection — to the protection provided by one of the most potent vaccines currently in use showed that reinfections were much less common. The paper from researchers in Israel contrasts with earlier studies, which showed that immunisation offered better protection than an earlier infection, though those studies were not of the Delta variant.
The results are good news for patients who already successfully battled Covid-19, but show the challenge of relying exclusively on immunisation to move past the pandemic. People given both doses of the Pfizer-BioNTech vaccine were almost six-fold more likely to contract a Delta infection and seven-fold more likely to have symptomatic disease than those who recovered.
“This analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalisation due to the Delta variant,” the researchers said.
The analysis also showed that protection from an earlier infection wanes with time. The risk of a vaccine-breakthrough Delta case was 13-fold higher than the risk of developing a second infection when the original illness occurred during January or February 2021. That’s significantly more than the risk for people who were ill earlier in the outbreak.
Giving a single shot of the vaccine to those who had been previously infected also appeared to boost their protection. The long-term benefit of a booster dose of the inoculation, which has just recently begun in Israel, is unknown.
The data was posted as a preprint article on medRxiv, and hasn’t yet been reviewed by other researchers.
Bloomberg News. More stories like this are available on Bloomberg.com
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.